翰森制药(03692) - 2025 - 年度业绩

Financial Performance - The company reported revenue of approximately RMB 15.028 billion, an increase of about 22.6% compared to the same period last year[4]. - Net profit for the year was approximately RMB 5.555 billion, an increase of about 27.1% compared to the previous year[4]. - Basic earnings per share were approximately RMB 0.93, reflecting a year-on-year increase of about 26.4%[4]. - Revenue from innovative drugs and collaborative products reached approximately RMB 12.354 billion, growing by about 30.4% year-on-year, accounting for approximately 82.2% of total revenue[4]. - The company recorded revenue of approximately RMB 15.028 billion for the year ended December 31, 2025, representing a year-on-year growth of approximately 22.6%[15]. - The group's net profit for the reporting period was approximately RMB 5.555 billion, representing a growth of about 27.1% compared to RMB 4.372 billion for the year ended December 31, 2024[69]. - The group's profit before tax reached RMB 5,555,461,000 in 2025, an increase of 27% compared to RMB 4,371,825,000 in 2024[102]. - Basic earnings per share for 2025 were RMB 0.93, compared to RMB 0.74 in 2024, representing a growth of approximately 25.7%[103]. Research and Development - R&D expenses were approximately RMB 3.358 billion, an increase of about 24.3% year-on-year, representing about 22.3% of total revenue[4]. - The company is conducting over 70 clinical trials for innovative drugs, with eight new candidates entering clinical research during the reporting period[36]. - Seven new Phase III pivotal clinical trials were initiated during the reporting period, including self-developed ADCs targeting B7-H3 and B7-H4 for osteosarcoma and ovarian cancer, respectively[37]. - The company has submitted 40 domestic patent applications and 128 overseas patent applications, with 80 patents granted globally as of December 31, 2025[35]. - The company invested RMB 3,357,981 in research and development, which is an increase from RMB 2,701,650 in the previous year[85]. - The average annual advancement of about eight innovative candidates to clinical trials from 2019 to 2025 demonstrates the company's efficient internal R&D and business expansion system[110]. Product Approvals and Collaborations - The company achieved a breakthrough therapy designation from the FDA for its self-developed ADC Risvutatug Rezetecan, aimed at treating relapsed or refractory osteosarcoma[6]. - The company received approval from the NMPA for its innovative drug HS-20093 for the treatment of advanced osteosarcoma after at least two lines of therapy[6]. - The company entered into a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop and commercialize its GLP-1/GIP dual receptor agonist HS-20094[9]. - The company received approval for three new indications for Aumseqa® (甲磺酸阿美替尼片) in 2025, expanding its treatment scope for NSCLC patients[17]. - A licensing agreement was established with Glenmark Specialty S.A. for the exclusive development and commercialization of Aumseqa® in several regions, including the Middle East and Africa[11]. - The company entered an exclusive licensing agreement with Glenmark, potentially earning over $1 billion in regulatory and commercial milestone payments for Aumseqa®[22]. - The company received a collaboration payment of $112 million from Merck Sharp & Dohme LLC during the reporting period[46]. Market and Sales Performance - Revenue from the oncology segment reached approximately RMB 9.974 billion, accounting for about 66.4% of total revenue[18]. - The company operates primarily in the Chinese pharmaceutical market, generating approximately 80% of its revenue from this sector[94]. - Revenue from pharmaceutical sales increased to RMB 12,912,719 thousand in 2025, up 20.9% from RMB 10,687,946 thousand in 2024[96]. - The company has a rich pipeline of seven innovative drugs generating sales revenue, focusing on major disease treatment areas such as oncology and CNS disorders[5]. Dividends and Financial Management - The company plans to distribute a final dividend of HKD 0.20 per share, pending approval at the annual general meeting, leading to a total dividend of HKD 0.4316 for the year[3]. - The group declared a final dividend of HKD 0.1353 per share for 2024, down from HKD 0.1422 per share in 2023, totaling approximately RMB 734,910,000[101]. - The company reported a foreign exchange loss of RMB 583,679 in other comprehensive income for the year, compared to a gain of RMB 234,447 in 2024[86]. Sustainability and Corporate Governance - The company achieved an MSCI ESG rating upgrade to AAA and was recognized in the top 1% of the Chinese pharmaceutical industry for sustainability efforts[12]. - The group’s administrative expenses amounted to approximately RMB 672 million, a decrease of about 5.7% compared to RMB 713 million for the year ended December 31, 2024, primarily due to enhanced cost control measures[64].